Table 4.
Adverse events during the follow-up period
| AS–AQ (N = 221) |
DHA–PPQ (N = 221) |
AM–LM (N = 221) |
p | ||||
|---|---|---|---|---|---|---|---|
| n | (%) | n | (%) | n | (%) | ||
| Fever | 90 | (40.7) | 94 | (42.5) | 94 | (42.5) | 0.906 |
| Cough | 31 | (14.0) | 36 | (16.3) | 22 | (10.0) | 0.141 |
| Rhinorrhoea | 20 | (9.1) | 27 | (12.2) | 17 | (7.7) | 0.255 |
| Diarrhoea | 19 | (8.6) | 14 | (6.4) | 15 | (6.8) | 0.624 |
| Conjunctivitis | 11 | (5.0) | 7 | (3.2) | 15 | (6.8) | 0.216 |
| Pyoderma | 12 | (5.4) | 6 | (2.7) | 6 | (2.7) | 0.211 |
| Vomit | 8 | (3.6) | 6 | (2.7) | 5 | (2.3) | 0.684 |
| Anorexia | 6 | (2.7) | 4 | (1.8) | 1 | (0.5) | 0.173 |
| Asthenia | 1 | (0.5) | 0 | (0.0) | 0 | (0.0) | 0.367 |
| Abdominal pain | 3 | (1.4) | 0 | (0.0) | 1 | (0.5) | 0.172 |
| Arthralgia | 1 | (0.5) | 0 | (0.0) | 0 | (0.0) | 0.367 |
| Headache | 1 | (0.5) | 0 | (0.0) | 0 | (0.0) | 0.367 |
| Convulsions | 1 | (0.5) | 0 | (0.0) | 0 | (0.0) | 0.367 |
| Hepatomegaly | 0 | (0.0) | 1 | (0.5) | 0 | (0.0) | 0.367 |
| Splenomegaly | 1 | (0.5) | 2 | (0.9) | 1 | (0.5) | 0.778 |
| Other events | 34 | (15.4) | 40 | (18.1) | 45 | (20.4) | 0.457 |